Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2016 (2016), Article ID 1764938, 8 pages
http://dx.doi.org/10.1155/2016/1764938
Research Article

Clumping and Viability of Bone Marrow Derived Mesenchymal Stromal Cells under Different Preparation Procedures: A Flow Cytometry-Based In Vitro Study

1Institute of Clinical Medicine-Neurology, University of Eastern Finland, 70210 Kuopio, Finland
2Department of Clinical Microbiology, Institute of Clinical Medicine, University of Eastern Finland, 70210 Kuopio, Finland
3Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany
4Fraunhofer Research Institution for Marine Biotechnology, 23562 Lübeck, Germany
5Institute for Medical and Marine Biotechnology, University of Lübeck, 23562 Lübeck, Germany
6Finnish Red Cross Blood Service, Advanced Cell Therapy Centre, 00310 Helsinki, Finland
7Neurocenter, Neurology, University Hospital of Kuopio, 70210 Kuopio, Finland

Received 27 November 2015; Revised 15 January 2016; Accepted 4 February 2016

Academic Editor: Shinn-Zong Lin

Copyright © 2016 Li-li Cui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. X. Bao, J. Wei, M. Feng et al., “Transplantation of human bone marrow-derived mesenchymal stem cells promotes behavioral recovery and endogenous neurogenesis after cerebral ischemia in rats,” Brain Research, vol. 1367, pp. 103–113, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. D. R. Yavagal, B. Lin, A. P. Raval et al., “Efficacy and dose-dependent safety of intra-arterial delivery of mesenchymal stem cells in a rodent stroke model,” PLoS ONE, vol. 9, no. 5, Article ID e93735, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Janowski, D. C. Wagner, and J. Boltze, “Stem cell-based tissue replacement after stroke: factual necessity or notorious fiction?” Stroke, vol. 46, no. 8, pp. 2354–2363, 2015. View at Publisher · View at Google Scholar
  4. J. Boltze, A. Arnold, P. Walczak, J. Jolkkonen, L. Cui, and D.-C. Wagner, “The dark side of the force—constraints and complications of cell therapies for stroke,” Frontiers in Neurology, vol. 6, article 155, 2015. View at Publisher · View at Google Scholar
  5. E. Eggenhofer, V. Benseler, A. Kroemer et al., “Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion,” Frontiers in Immunology, vol. 3, article 297, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Tatsumi, K. Ohashi, Y. Matsubara et al., “Tissue factor triggers procoagulation in transplanted mesenchymal stem cells leading to thromboembolism,” Biochemical and Biophysical Research Communications, vol. 431, no. 2, pp. 203–209, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Misra, M. M. Ritchie, L. L. Stone, W. C. Low, and V. Janardhan, “Stem cell therapy in ischemic stroke: role of IV and intra-arterial therapy,” Neurology, vol. 79, supplement 1, no. 13, pp. S207–S212, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Lundberg, E. Södersten, E. Sundström et al., “Targeted intra-arterial transplantation of stem cells to the injured CNS is more effective than intravenous administration: engraftment is dependent on cell type and adhesion molecule expression,” Cell Transplantation, vol. 21, no. 1, pp. 333–343, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. P. H. Lee, J. W. Kim, O. Y. Bang, Y. H. Ahn, I. S. Joo, and K. Huh, “Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy,” Clinical Pharmacology and Therapeutics, vol. 83, no. 5, pp. 723–730, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Walczak, J. Zhang, A. A. Gilad et al., “Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia,” Stroke, vol. 39, no. 5, pp. 1569–1574, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Janowski, A. Lyczek, C. Engels et al., “Cell size and velocity of injection are major determinants of the safety of intracarotid stem cell transplantation,” Journal of Cerebral Blood Flow and Metabolism, vol. 33, no. 6, pp. 921–927, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. L. L. Cui, E. Kerkelä, A. Bakreen et al., “The cerebral embolism evoked by intra-arterial delivery of allogeneic bone marrow mesenchymal stem cells in rats is related to cell dose and infusion velocity,” Stem Cell Research & Therapy, vol. 6, article 11, 2015. View at Publisher · View at Google Scholar
  13. J. Ge, L. Guo, S. Wang et al., “The size of mesenchymal stem cells is a significant cause of vascular obstructions and stroke,” Stem Cell Reviews and Reports, vol. 10, no. 2, pp. 295–303, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. D. H. Hickerson, H. S. White, A. Nguyen et al., “Development of a flow cytometry-based pulse-width assay for detection of aggregates in cellular therapeutics to be infused by catheter,” Cytotherapy, vol. 16, no. 11, pp. 1545–1557, 2014. View at Publisher · View at Google Scholar
  15. C. V. Borlongan, S. Saporta, S. G. Poulos, A. Othberg, and P. R. Sanberg, “Viability and survival of hNT neurons determine degree of functional recovery in grafted ischemic rats,” NeuroReport, vol. 9, no. 12, pp. 2837–2842, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Khabbal, E. Kerkelä, B. Mitkari et al., “Differential clearance of rat and human bone marrow-derived mesenchymal stem cells from the brain after intra-arterial infusion in rats,” Cell Transplantation, vol. 24, no. 5, pp. 819–828, 2015. View at Publisher · View at Google Scholar
  17. J. M. Karp and G. S. Leng Teo, “Mesenchymal stem cell homing: the devil is in the details,” Cell Stem Cell, vol. 4, no. 3, pp. 206–216, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. The Stem Cell Therapies as an Emerging Paradigm in Stroke Participants, “Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke,” Stroke, vol. 40, no. 2, pp. 510–515, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. S. I. Savitz, M. Chopp, R. Deans, S. T. Carmichael, D. Phinney, and L. Wechsler, “Stem cell therapy as an emerging paradigm for stroke (STEPS) II,” Stroke, vol. 42, no. 3, pp. 825–829, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Fukuda, N. Horie, K. Satoh et al., “Intra-arterial transplantation of low-dose stem cells provides functional recovery without adverse effects after stroke,” Cellular and Molecular Neurobiology, vol. 35, no. 3, pp. 399–406, 2015. View at Publisher · View at Google Scholar
  21. G. Moll, I. Rasmusson-Duprez, L. von Bahr et al., “Are therapeutic human mesenchymal stromal cells compatible with human blood?” Stem Cells, vol. 30, no. 7, pp. 1565–1574, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Guo, J. Ge, Y. Zhou, S. Wang, R. C. H. Zhao, and Y. Wu, “Three-dimensional spheroid-cultured mesenchymal stem cells devoid of embolism attenuate brain stroke injury after intra-arterial injection,” Stem Cells and Development, vol. 23, no. 9, pp. 978–989, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Xu, S. W. Du, X. G. Yu, X. Han, J. C. Hou, and H. Guo, “Human bone marrow mesenchymal stem cell transplantation attenuates axonal injury in stroke rats,” Neural Regeneration Research, vol. 9, no. 23, pp. 2053–2058, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Moll, J. J. Alm, L. C. Davies et al., “Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?” Stem Cells, vol. 32, no. 9, pp. 2430–2442, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. M. François, I. B. Copland, S. Yuan, R. Romieu-Mourez, E. K. Waller, and J. Galipeau, “Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing,” Cytotherapy, vol. 14, no. 2, pp. 147–152, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. F. F. Cruz, Z. D. Borg, M. Goodwin et al., “Freshly thawed and continuously cultured human bone marrow-derived mesenchymal stromal cells comparably ameliorate allergic airways inflammation in immunocompetent mice,” Stem Cells Translational Medicine, vol. 4, no. 6, pp. 615–624, 2015. View at Publisher · View at Google Scholar
  27. J. Luetzkendorf, K. Nerger, J. Hering et al., “Cryopreservation does not alter main characteristics of Good Manufacturing Process-grade human multipotent mesenchymal stromal cells including immunomodulating potential and lack of malignant transformation,” Cytotherapy, vol. 17, no. 2, pp. 186–198, 2015. View at Publisher · View at Google Scholar · View at Scopus